SCHEMBL25623330

C#CCOCCOCCOCCOCCC(=O)N(CC(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@H](CO)C(=O)NC[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O)CC(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@H](CO)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O

nearest known ligand 0.64

Predicted protein targets (top 10)

	gene	UniProt	supporting neighbours	confidence
▸	KDM1A	O60341	3/20	0.64

▸	RCOR1	Q9UKL0	2/20	0.64

▸	SSTR2	P30874	4/20	0.40

▸	SSTR1	P30872	3/20	0.40

▸	SSTR4	P31391	3/20	0.40

▸	SSTR3	P32745	3/20	0.40

▸	SSTR5	P35346	3/20	0.40

▸	TERF2IP	Q9NYB0	9/20	0.39

▸	MDM2	Q00987	3/20	0.37

▸	F11	P03951	1/20	0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL25623302	0.94	KDM1A (0.65)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL26181706	0.88	KDM1A (0.78)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL25622799	0.85	KDM1A (0.72)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL21476968	0.83	KDM1A (0.87)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL21474117	0.83	KDM1A (0.87)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL26181847	0.83	KDM1A (0.67)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL26181835	0.82	KDM1A (0.65)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL25582800	0.82	KDM1A (0.64)	KDM1ARCOR1SSTR2SSTR4SSTR5
SCHEMBL25586072	0.82	KDM1A (0.68)	KDM1ARCOR1SSTR2SSTR1SSTR4
SCHEMBL25582813	0.82	KDM1A (0.65)	KDM1ARCOR1TERF2IPMDM2F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230165970-A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS	CIDARA THERAPEUTICS, INC.	2023-06-01	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230165970-A1	COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS	FCGR3B, FCGR1A, FCGR2A	KDM1A 4789/4885RCOR1 4863/4885SSTR2 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.